Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.

Authors :: Mato A
Jauhari S
Schuster SJ
Source :: American journal of hematology [Am J Hematol] 2015 Jul; Vol. 90 (7), pp. 657-64. Date of Electronic Publication: 2015 May 28.
Publication Year :: 2015
Abstract: The treatment of patients with chronic lymphocytic leukemia (CLL), an indolent B-cell lymphoma is in the midst of a transformation. There are a large number of promising new therapeutic agents and cellular therapies being studied which exhibit remarkable activity, favorable toxicity profiles, convenient administration schedules, and treatment options are rapidly expanding. The recent advances in the management of CLL exemplify the value of translational medicine. This review highlights key aspects of B-cell receptor (BCR) signaling in relation to novel inhibitors of the BCR signaling pathway, currently at various stages of preclinical and clinical development.<br /> (© 2015 Wiley Periodicals, Inc.)

Subjects :: Agammaglobulinaemia Tyrosine Kinase
Antibodies, Monoclonal therapeutic use
Antimetabolites, Antineoplastic therapeutic use
B-Lymphocytes drug effects
B-Lymphocytes metabolism
B-Lymphocytes pathology
Gene Expression Regulation
Humans
Leukemia, Lymphocytic, Chronic, B-Cell genetics
Leukemia, Lymphocytic, Chronic, B-Cell metabolism
Leukemia, Lymphocytic, Chronic, B-Cell pathology
Phosphatidylinositol 3-Kinases genetics
Phosphatidylinositol 3-Kinases metabolism
Protein Kinase Inhibitors therapeutic use
Protein-Tyrosine Kinases genetics
Protein-Tyrosine Kinases metabolism
Receptors, Antigen, B-Cell genetics
Receptors, Antigen, B-Cell metabolism
Signal Transduction drug effects
Antineoplastic Agents therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Phosphoinositide-3 Kinase Inhibitors
Protein-Tyrosine Kinases antagonists & inhibitors
Receptors, Antigen, B-Cell antagonists & inhibitors

Full Text Access

Tools